Effect of oridonin on cell proliferation, migration, and apoptosis of human nasopharynx carcinoma HONE-1 cells

Chao LIANG,Juanjuan DAI,Ning ZHOU,Dandan WANG,Jie ZHAO,Di AN,Yan WU

PDF(727 KB)
PDF(727 KB)
J Jilin Univ Med Ed ›› 2024, Vol. 50 ›› Issue (4) : 917-924. DOI: 10.13481/j.1671-587X.20240405
Research in basic medicine

Effect of oridonin on cell proliferation, migration, and apoptosis of human nasopharynx carcinoma HONE-1 cells

  • Chao LIANG1,2,Juanjuan DAI2,Ning ZHOU3,Dandan WANG1,2,Jie ZHAO1,2,Di AN1,2,Yan WU1,2()
Author information +
History +

Abstract

Objective To discuss the effect of oridonin on the proliferation, migration, epithelial-mesenchymal transition (EMT), and apoptosis of the human nasopharyngeal carcinoma HONE-1 cells, and to clarify its related antitumor mechanism. Methods The HONE-1 cells were treated with different concentrations (0, 5, 10, 20, 40, 80, and 160 mg·L-1) of oridonin for 48 h. CCK-8 method was used to detect the inhibitory rates of proliferation of the cells in various groups and the drug concentration for subsequent experiment was confirmed.The HONE-1 cells were divided into control group, 3 mg·L-1 oridonin group, and 6 mg·L-1 oridonin group. After 24 and 48 h of culture, CCK-8 method was used to detect the proliferation activities of the cells in various groups; 5-ethynyl-2'-deoxyuridine (EdU) method was used to detect the rates of EdU-positive cells in various groups; colony formation assay was used to detect the numbers of clone formation in the cells in various groups; Transwell chamber experiment and cell wound assay were used to detect the numbers of migration cells and the scratch healing rates of the cells in various groups; real-time fluorescence quantitative PCR (RT-qPCR) method was used to detect the expression levels of cyclin-dependent kinase 1 (CDK1) and cyclin-dependent kinase 4 (CDK4) mRNA in the cells in various groups; Western blotting method was used to detect the expression levels of E-cadherin, Vimentin, Caspase-3, and poly ADP-ribose polymerase 1 (PARP1) proteins in the cells in various groups. Results The CCK-8 method results showed that the half-maximal inhibitory concentration (IC50) of oridonin at 48 h was 12.18 mg·L-1,and 1/4 IC50 and 1/2 IC50 values were used as the concentrations for subsequent experiments. Compared with control group, after treated for 24 and 48 h, the proliferation activities of the cells in 3 and 6 mg·L-1 oridonin groups were decreased (P<0.05 or P<0.01), the rate of EdU-positive cells were decreased (P<0.05 or P<0.01), the numbers of clone formation and migraton cells were decreased (P<0.05 or P<0.01), the scratch healing rates were decreased (P<0.05 or P<0.01), the expression levels of CDK1 and CDK4 mRNA in the cells were decreased (P<0.05 or P<0.01), the expression levels of E-cadherin, Caspase-3, and PARP1 proteins were increased (P<0.05 or P<0.01), and the expression levels of Vimentin protein were decreased (P<0.05). Conclusion Oridonin can inhibit the proliferation, clone formation, and migration of the human nasopharyngeal carcinoma HONE-1 cells by downregulating the expression of cell cycle-related proteins and EMT, and promote the apoptosis to exert an antitumor effect.

Key words

Oridonin / Nasopharyngeal neoplasm / Cell cycle / Epithelial-Mesenchymal transit / Apoptosis

CLC number

R285.5

Cite this article

Download Citations
Chao LIANG,Juanjuan DAI,Ning ZHOU,Dandan WANG,Jie ZHAO,Di AN,Yan WU. Effect of oridonin on cell proliferation, migration, and apoptosis of human nasopharynx carcinoma HONE-1 cells. Journal of Jilin University(Medicine Edition). 2024, 50(4): 917-924 https://doi.org/10.13481/j.1671-587X.20240405

References

1 SUN L L, SONG J J, HUANG Q L. Clinicopathological and prognostic significance of p16 protein in nasopharynx cancer patients: a PRISMA-compliant meta-analysis [J]. Medicine (Baltimore), 2019, 98(11): e14602.
2 BAI R H, SUN J Z, XU Y, et al. Incidence and mortality trends of nasopharynx cancer from 1990 to 2019 in China: an age-period-cohort analysis[J]. BMC Public Health, 2022, 22(1): 1351.
3 MAHDAVIFAR N, GHONCHEH M, MOHAMMADIAN-HAFSHEJANI A, et al. Epidemiology and inequality in the incidence and mortality of nasopharynx cancer in Asia[J]. Osong Public Health Res Perspect, 2016, 7(6): 360-372.
4 LIU G S, ZHANG S M, MA Y Z, et al. Effects of error on dose of target region and organs at risk in treating nasopharynx cancer with intensity modulated radiation therapy[J]. Pak J Med Sci, 2016, 32(1): 95-100.
5 AN Y P, ZHU J, WANG X, et al. Oridonin delays aging through the AKT signaling pathway[J]. Front Pharmacol, 2022, 13: 888247.
6 LI C Y, ZHU Y H, WU Y Y, et al. Oridonin alleviates LPS-induced depression by inhibiting NLRP3 inflammasome via activation of autophagy[J]. Front Med, 2021, 8: 813047.
7 LI X, ZHANG C T, MA W, et al. Oridonin: a review of its pharmacology, pharmacokinetics and toxicity[J]. Front Pharmacol, 2021, 12: 645824.
8 LI D H, HAN T, LIAO J, et al. Oridonin, a promising ent-kaurane diterpenoid lead compound[J]. Int J Mol Sci, 2016, 17(9): 1395.
9 HONG M K, LIU H H, CHEN G H, et al. Oridonin alters hepatic urea cycle via gut microbiota and protects against acetaminophen-induced liver injury[J]. Oxid Med Cell Longev, 2021, 2021: 3259238.
10 PARK H, JEONG Y J, HAN N K, et al. Oridonin enhances radiation-induced cell death by promoting DNA damage in non-small cell lung cancer cells[J]. Int J Mol Sci, 2018, 19(8): 2378.
11 LI S R, SHI D, ZHANG L Y, et al. Oridonin enhances the radiosensitivity of lung cancer cells by upregulating Bax and downregulating Bcl-2[J]. Exp Ther Med, 2018, 16(6): 4859-4864.
12 LIU W, WANG X D, WANG L, et al. Oridonin represses epithelial-mesenchymal transition and angiogenesis of thyroid cancer via downregulating JAK2/STAT3 signaling[J]. Int J Med Sci, 2022, 19(6): 965-974.
13 LUO D D, YI Y J, PENG K, et al. Oridonin derivatives as potential anticancer drug candidates triggering apoptosis through mitochondrial pathway in the liver cancer cells[J]. Eur J Med Chem, 2019, 178: 365-379.
14 何 静, 严如根, 金国钰, 等. 冬凌草甲素体内外抗卵巢癌活性及相关机制研究[J]. 郑州大学学报(医学版),2023, 58(4): 480-489.
15 TCHAKARSKA G, SOLA B. The double dealing of cyclin D1[J]. Cell Cycle, 2020, 19(2): 163-178.
16 CHEN N P, ARETZ J, F?SSLER R. CDK1-cyclin-B1-induced kindlin degradation drives focal adhesion disassembly at mitotic entry[J]. Nat Cell Biol, 2022, 24(5): 723-736.
17 YIN Q Y, JIAN Y L, XU M, et al. CDK4/6 regulate lysosome biogenesis through TFEB/TFE3[J]. J Cell Biol, 2020, 219(8): e201911036.
18 SINGH M, YELLE N, VENUGOPAL C, et al. EMT: mechanisms and therapeutic implications[J]. Pharmacol Ther, 2018, 182: 80-94.
19 SOMMARIVA M, GAGLIANO N. E-cadherin in pancreatic ductal adenocarcinoma: a multifaceted actor during EMT[J]. Cells, 2020, 9(4): 1040.
20 HASHEMI M, ARANI H Z, OROUEI S, et al. EMT mechanism in breast cancer metastasis and drug resistance: Revisiting molecular interactions and biological functions[J]. Biomed Pharmacother, 2022, 155: 113774.
21 BRABLETZ S, SCHUHWERK H, BRABLETZ T, et al. Dynamic EMT: a multi-tool for tumor progression[J]. EMBO J, 2021, 40(18): e108647.
22 ESKANDARI E, EAVES C J. Paradoxical roles of caspase-3 in regulating cell survival, proliferation, and tumorigenesis[J]. J Cell Biol, 2022, 221(6): e202201159.
23 ARRURI V K, GUNDU C, KHAN I, et al. PARP overactivation in neurological disorders[J]. Mol Biol Rep, 2021, 48(3): 2833-2841.
24 WANG Y, LUO W, WANG Y. PARP-1 and its associated nucleases in DNA damage response[J]. DNA Repair (Amst), 2019, 81: 102651.

Comments

PDF(727 KB)

Accesses

Citation

Detail

Sections
Recommended

/